Evidence map›Paper›PMID 37242568›Full record

ArticlePharmaceutics2023

Glutathione-Responsive Tannic Acid-Assisted FRET Nanomedicine for Cancer Therapy.

Partha Laskar, Anupam Dhasmana, Sudhir Kotnala, Meena Jaggi, Murali M Yallapu, Subhash C Chauhan

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Partha LaskarDepartment of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
Anupam DhasmanaDepartment of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
Sudhir KotnalaDepartment of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.ORCID 0000-0001-7070-532X
Meena JaggiDepartment of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
Murali M YallapuDepartment of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.ORCID 0000-0002-0073-8828
Subhash C ChauhanDepartment of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
The University of Texas Rio Grande Valley · USSwami Rama Himalayan University · INUppsala University · SE

Funding

Development of Targeted Nanotechnology Platform for Pancreatic CancerR01CA206069 · NCI · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CHAUHAN, SUBHASH C. · 2016 to 2021
$1.7M
Targeted Nanotherapy for Pancreatic CancerR01CA210192 · NCI · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI CHAUHAN, SUBHASH C. · 2016 to 2021
$1.7M
miR-205 Nanoparticle system circumvents docetaxel resistance in prostate cancerSC1GM139727 · NIGMS · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI YALLAPU, MURALI MOHAN · 2021 to 2024
$1.5M
NCI NIH HHS R01 CA206069NCI NIH HHS R01 CA210192NIGMS NIH HHS SC1 GM139727NIH HHS CA210192, CA206069, and GM139727
6 · The paper itself

Abstract

In cancer combination therapy, a multimodal delivery vector is used to improve the bioavailability of multiple anti-cancer hydrophobic drugs. Further, targeted delivery of therapeutics along with simultaneous monitoring of the drug release at the tumor site without normal organ toxicity is an emerging and effective strategy for cancer treatment. However, the lack of a smart nano-delivery system limits the application of this therapeutic strategy. To overcome this issue, a PEGylated dual drug, conjugated amphiphilic polymer (CPT-S-S-PEG-CUR), has been successfully synthesized by conjugating two hydrophobic fluorescent anti-cancer drugs, curcumin (CUR) and camptothecin (CPT), through an ester and a redox-sensitive disulfide (-S-S-) linkage, respectively, with a PEG chain via in situ two-step reactions. CPT-S-S-PEG-CUR is spontaneously self-assembled in the presence of tannic acid (TA, a physical crosslinker) into anionic, comparatively smaller-sized (~100 nm), stable nano-assemblies in water in comparison to only polymer due to stronger H-bond formation between polymer and TA. Further, due to the spectral overlap between CPT and CUR and a stable, smaller nano-assembly formation by the pro-drug polymer in water in presence of TA, a successful Fluorescence Resonance Energy Transfer (FRET) signal was generated between the conjugated CPT (FRET donor) and conjugated CUR (FRET acceptor). Interestingly, these stable nano-assemblies showed a preferential breakdown and release of CPT in a tumor-relevant redox environment (in the presence of 50 mM glutathione), leading to the disappearance of the FRET signal. These nano-assemblies exhibited a successful cellular uptake by the cancer cells and an enhanced antiproliferative effect in comparison to the individual drugs in cancer cells (AsPC1 and SW480). Such promising in vitro results with a novel redox-responsive, dual-drug conjugated, FRET pair-based nanosized multimodal delivery vector can be highly useful as an advanced theranostic system towards effective cancer treatment.

Indexed as

camptothecincombination cancer therapycurcuminFRETglutathione-responsive nanoparticletannic acid

Identifiers

PMID37242568
PMCPMC10222396
OpenAlexW4366827459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.